ESPE Yearbook of Paediatric Endocrinology

Pediatr Blood Cancer. 2020; 67: e28617. https://pubmed.ncbi.nlm.nih.gov/32715632/This retrospective single-centre study aimed to develop a final height prediction model based on data from 212 long-term survivors (aged 5-20.4 years) of childhood central nervous system (CNS) tumors who received craniospinal irradiation (CSI) and with a median follow up of 10.2 years. Mean fin...

J Clin Endocrinol Metab. 2022 Jan 1;107(1):109-118.Abstract: https://pubmed-ncbi-nlm-nih-gov/34498693/In Brief: This study established a standard range of Inorganic Pyrophosphate (PPi) between 2.36 and 4.44 µM (5th-95th percentiles) in the blood plasma of children and adolescents aged 0 to 18 years, using the ATP sulfurylase assay. There was no sex difference and the range is similar t...

Nat Med. 2021 Dec;27(12):2104-2107. https://pubmed.ncbi.nlm.nih.gov/34887578/Brief Summary: This study used single-cell transcriptomic analyses to generate a cell atlas of the human fetal and neonatal small intestine. Notably, the authors identified a subset of fetal enteroendocrine K/L cells (named FIKL) that express high levels of insulin and other beta cell genes.T...

Brief summary: The authors used data from the Global Burden of Disease 2019 to examine the incidence, disability adjusted life years and mortality of early onset type 2 diabetes T2D) in those 15–39 years of age. This showed that early onset T2D is a growing global health problem in adolescents and young adults, particularly in low-middle- and middle-income countries.Early onset of type 2 diabetes (T2D) is associated with longer lifetime exposure hyp...

Brief summary: The authors developed a model to estimate the worldwide prevalence of Type 1 diabetes (T1D) in 2040. Compared to 2021, when an estimated 8.4 million individuals had T1D (including 18% < 20 years), the prevalent cases are expected to increase to 13.5–17.4 million in 2040, with the largest relative increase taking place in low- and middle-income countries.This model, using published data (available from only 97 countries worldwide) ...

Brief summary: In this in vivo study, Xia et al. demonstrate that AAV-mediated gene therapy recovers testosterone levels, restarts sexual development, restores spermatogenesis, and produces fertile offspring in a mouse model of Leydig cell failure (LCF).A null mutation in the gene encoding luteinizing hormone/choriogonadotrophin receptor (Lhcgr) causes a hereditary LCF in mice which is characterized by a reduction in testosterone levels...